Cwm LLC Makes New $242,000 Investment in Sera Prognostics, Inc. (NASDAQ:SERA)

Cwm LLC purchased a new position in shares of Sera Prognostics, Inc. (NASDAQ:SERA) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 40,524 shares of the company’s stock, valued at approximately $242,000. Cwm LLC owned about 0.13% of Sera Prognostics as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Perigon Wealth Management LLC acquired a new position in shares of Sera Prognostics during the 4th quarter worth approximately $509,000. Vanderbilt University bought a new stake in shares of Sera Prognostics during the 4th quarter valued at $284,000. Finally, Resource Consulting Group Inc. bought a new stake in shares of Sera Prognostics during the 4th quarter valued at $265,000. 54.64% of the stock is owned by institutional investors and hedge funds.

Sera Prognostics Stock Performance

NASDAQ:SERA opened at $10.85 on Friday. The stock has a fifty day moving average price of $9.57 and a 200-day moving average price of $6.43. The company has a market cap of $351.87 million, a price-to-earnings ratio of -9.35 and a beta of 1.33. Sera Prognostics, Inc. has a fifty-two week low of $1.52 and a fifty-two week high of $12.35.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings data on Wednesday, March 20th. The company reported ($0.25) earnings per share for the quarter, hitting the consensus estimate of ($0.25). Sera Prognostics had a negative return on equity of 45.74% and a negative net margin of 11,843.79%. The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.10 million. Research analysts predict that Sera Prognostics, Inc. will post -0.94 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Paul Kearney sold 4,984 shares of the company’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $8.03, for a total transaction of $40,021.52. Following the completion of the sale, the insider now directly owns 160,066 shares in the company, valued at approximately $1,285,329.98. The sale was disclosed in a filing with the SEC, which is available through this link. In other Sera Prognostics news, insider Paul Kearney sold 4,984 shares of the company’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $8.03, for a total value of $40,021.52. Following the completion of the transaction, the insider now owns 160,066 shares of the company’s stock, valued at approximately $1,285,329.98. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, General Counsel Benjamin Jackson sold 5,665 shares of the company’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $8.03, for a total value of $45,489.95. Following the completion of the transaction, the general counsel now directly owns 152,035 shares of the company’s stock, valued at approximately $1,220,841.05. The disclosure for this sale can be found here. Insiders sold a total of 141,335 shares of company stock worth $1,255,192 in the last ninety days. 15.60% of the stock is owned by insiders.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.